Prognostic and surrogate markers for outcome in the treatment of pulmonary tuberculosis
Phase III trials for new tuberculosis treatment regimens require large numbers of participants and can take over five years to complete. A surrogate marker for poor outcome (failure at end of treatment or recurrence following successful treatment), the established endpoint in such trials, could shor...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
London School of Hygiene and Tropical Medicine (University of London)
2009
|
| Subjects: | |
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.536901 |